3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
300
Carcinoma, Non-Small-Cell Lung
262
Neoplasms
242
Prostatic Neoplasms
204
Colorectal Neoplasms
187
Lung Neoplasms
145
Multiple Myeloma
141
Neoplasm Metastasis
126
Ovarian Neoplasms
123
Leukemia, Myeloid, Acute
115
Pancreatic Neoplasms
109
Melanoma
96
Squamous Cell Carcinoma of Head and Neck
93
Recurrence
80
Endometrial Neoplasms
78
Carcinoma, Renal Cell
76
Lymphoma, Non-Hodgkin
74
Lymphoma
70
Stomach Neoplasms
69
Precursor Cell Lymphoblastic Leukemia-Lymphoma
69
Carcinoma, Hepatocellular
67
Glioblastoma
66
Brain Neoplasms
64
Sarcoma
62
Glioma
62
Uterine Cervical Neoplasms
59
Head and Neck Neoplasms
59
Triple Negative Breast Neoplasms
57
Leukemia, Lymphocytic, Chronic, B-Cell
54
Urinary Bladder Neoplasms
51
Interventions
ribociclib
1
palbociclib
1
capivasertib
1
abemaciclib
1
Fulvestrant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Locally Advanced (Inoperable) or Metastatic Breast Cancer
×
30 days
×
Clear all
NCT04862663
2026-05-27
CAPItello-292
AstraZeneca
Phase 3
Recruiting
895 enrolled